French medicinal chemistry SME providing proprietary compound libraries and HTS expertise for DNA-repair and genome-stability drug discovery programs.
EDELRIS is a Lyon-based medicinal chemistry and chemical biology SME specializing in the design and synthesis of small-molecule compound libraries for drug discovery. Their core offering is proprietary chemical libraries tailored for high-throughput screening against biological targets, making them a specialist service provider for academic and industrial drug discovery programs. In their EU project work, they contributed chemical library assets and screening expertise to campaigns targeting DNA-processing enzymes, particularly helicases involved in genome maintenance. They operate at the interface of chemistry and biology, translating biological target hypotheses into screenable chemical matter.
ESCulab (2018) was built explicitly around a unique compound library for attractive biology, while AntiHelix (2019) applied this screening capability to DNA helicase inhibitor discovery.
AntiHelix directly tasked EDELRIS with identifying specific small-molecule inhibitors of DNA helicases involved in DNA replication, repair, and recombination.
AntiHelix keywords cover DNA replication, repair, recombination, and helicase enzymes — a tightly defined mechanistic area where EDELRIS contributed chemical matter expertise.
ESCulab was a pan-European effort to create a shared screening centre with a unique library, positioning EDELRIS as a contributor to open-innovation drug discovery infrastructure.
EDELRIS entered H2020 through ESCulab (2018) with a broad high-throughput screening capability focus — their role was to provide chemical libraries to a European screening platform serving diverse biological targets. By 2019, their second project AntiHelix narrowed the focus sharply to a specific mechanistic class: DNA helicases and genome stability enzymes, with the explicit goal of developing targeted inhibitors. This suggests a strategic shift from being a general-purpose screening chemistry provider toward becoming a specialist in DNA-damage pathway chemical biology, likely because this target class proved commercially attractive or scientifically productive for them.
EDELRIS appears to be moving from broad screening-platform participation toward focused mechanistic drug discovery in the DNA repair and genome stability space, which aligns with growing oncology and rare-disease interest in this target class.
EDELRIS has participated exclusively as a consortium partner, never as a project coordinator, which is consistent with their role as a specialist chemistry provider rather than a project driver. Despite only two projects, they have accumulated 25 unique partners across 9 countries — an unusually wide network for such a small participation footprint, suggesting they join large, multi-partner consortia where their library and screening assets are a shared resource. This pattern indicates they are most useful to consortia that need a dedicated chemistry contributor rather than a leadership organization.
EDELRIS has engaged with 25 distinct consortium partners across 9 countries despite only two projects, reflecting participation in large European research networks. Their geographic spread suggests European-scale collaboration rather than a local or bilateral focus.
EDELRIS occupies a rare niche as an SME that owns proprietary compound libraries purpose-built for biological screening, a capability that most academic partners in drug discovery consortia cannot provide in-house. Their positioning as a chemistry-to-biology bridge makes them a practical asset in any consortium targeting enzymes or proteins where a screening campaign is part of the work plan. For consortium builders in oncology, infectious disease, or rare genetic disorders involving DNA-repair pathways, EDELRIS brings ready-to-use chemical tools that accelerate the discovery phase without requiring partners to build that infrastructure themselves.
